Funding for this research was provided by:
National Institute on Aging (RF1 AG058657, R01 AG040092)
Received: 23 October 2019
Accepted: 30 December 2019
First Online: 13 January 2020
Ethics approval and consent to participate
: Animal studies performed in the Lemere Lab were approved by the Harvard Standing Committee for Animal Use and was in compliance with all state and federal regulations. The Harvard Medical School animal management program is accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International (AALAC) and meets all National Institutes of Health standards as demonstrated by an approved Assurance of Compliance (A3431-01) filed at the Office of Laboratory Animal Welfare. Animal studies performed at the AAALAC-accredited QPS Austria GmbH site conformed to the Austrian guidelines for the care and use of laboratory animals and were approved by the Styrian government, Austria.
: Not applicable.
: According to the journal’s requirements, we hereby declare that Martin Kleinschmidt, Jens-Ulrich Rahfeld, Stephan Schilling, and Inge Lues are former and Thore Hettmann, present, employees of Vivoryon Therapeutics AG, Germany and hold stock options of the company. Jens-Ulrich Rahfeld and Stephan Schilling are advisors to Vivoryon Therapeutics AG. Senior author, Cynthia A. Lemere, was an unpaid scientific advisory board member for Vivoryon Therapeutics AG, receives antibodies, and has previously received unrestricted funding from Vivoryon Therapeutics AG for some of her past work on pGlu-3 Aβ immunotherapy. She has also served as a consultant to Biogen.